Skip to main content
HLB Therapeutics Co.,Ltd. logo

HLB Therapeutics Co.,Ltd. — Investor Relations & Filings

Ticker · 115450 ISIN · KR7115450009 KO Manufacturing
Open in API
Filings indexed 444 across all filing types
Latest filing 2025-01-02 M&A Activity
Country KR South Korea
Listing KO 115450

About HLB Therapeutics Co.,Ltd.

https://hlbtherapeutics.co.kr/en/

HLB Therapeutics Co., Ltd. is a biopharmaceutical company specializing in the development of innovative, first-in-class drugs for rare and intractable diseases. The company's clinical-stage pipeline focuses on addressing unmet medical needs in ophthalmology and oncology. Key development programs include RGN-259, a therapeutic agent for Dry Eye Disease and Neurotrophic Keratopathy, and OKN-007 for the treatment of Glioblastoma Multiforme. Additionally, the company is advancing a Natural Killer (NK) cell therapy through late-stage clinical trials to provide new therapeutic options for patients.

Recent filings

Filing Released Lang Actions
합병등종료보고서(분할)
M&A Activity Classification · 100% confidence The document is a 'Report on the Completion of Merger/Split' (합병등종료보고서) filed with the Financial Supervisory Service (FSS) in South Korea. It details the finalization of a corporate split (division) process, including the timeline, shareholder appraisal rights, and pro-forma financial statements post-split. As this is a formal regulatory filing documenting the completion of a corporate restructuring event (M&A/Split), it falls under the 'M&A Activity' category.
2025-01-02 Korean
전환가액의조정 (제16회차)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from HLB Therapeutics regarding the adjustment of the conversion price for its 16th series convertible bonds. This type of filing, which details changes to capital structure instruments (specifically conversion price adjustments due to market price fluctuations), falls under the category of capital and financing updates. It is not a report publication announcement, but rather the primary disclosure of the financial event itself.
2025-01-02 Korean
주요사항보고서(무상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Korean financial authorities (Financial Services Commission/Korea Exchange) regarding a 'Decision on Bonus Issue' (무상증자결정). This document details the issuance of new shares to existing shareholders, which falls under capital changes. According to the provided filing definitions, announcements regarding new share issues or capital changes are classified as 'Share Issue/Capital Change' (SHA).
2024-12-19 Korean
주주명부폐쇄기간또는기준일설정
Share Issue/Capital Change Classification · 100% confidence The document is a formal notice regarding the setting of a record date for shareholder registry closure, specifically for the purpose of a bonus issue (free share distribution). This type of corporate action announcement, which informs shareholders of upcoming capital changes and record dates, is classified as a regulatory filing related to share capital changes or general corporate announcements. Given the specific nature of the notice regarding share issuance and the lack of a full report, it falls under the RNS category as a general regulatory announcement.
2024-12-19 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a formal announcement of a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결) by HLB Therapeutics. It details the contract value, the counterparty (Public Procurement Service), the contract period, and payment terms. Since this is a specific regulatory disclosure regarding a material business contract that does not fit into the other specialized categories like M&A or share issues, it falls under the general regulatory filing category.
2024-12-18 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for the purpose of the upcoming Annual General Meeting. It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of the administrative procedure for shareholder rights. Given it is a standard regulatory notification regarding corporate governance procedures, it fits best under the RNS category.
2024-12-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.